Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by US Bancorp DE

US Bancorp DE reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 6.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,593 shares of the medical research company’s stock after selling 635 shares during the period. US Bancorp DE’s holdings in Bio-Rad Laboratories were worth $3,210,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. First Trust Direct Indexing L.P. acquired a new position in Bio-Rad Laboratories in the third quarter valued at approximately $277,000. New York State Teachers Retirement System raised its holdings in shares of Bio-Rad Laboratories by 7.1% during the third quarter. New York State Teachers Retirement System now owns 17,300 shares of the medical research company’s stock valued at $5,788,000 after buying an additional 1,142 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Bio-Rad Laboratories by 58.5% during the third quarter. Nisa Investment Advisors LLC now owns 872 shares of the medical research company’s stock valued at $292,000 after buying an additional 322 shares during the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Bio-Rad Laboratories by 341.7% during the third quarter. Louisiana State Employees Retirement System now owns 5,300 shares of the medical research company’s stock valued at $1,773,000 after buying an additional 4,100 shares during the last quarter. Finally, Ballentine Partners LLC bought a new stake in shares of Bio-Rad Laboratories during the third quarter valued at approximately $227,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.50% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $374.28 on Wednesday. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $376.38. The stock has a market cap of $10.43 billion, a price-to-earnings ratio of -13.69 and a beta of 0.93. The stock’s 50 day moving average price is $335.10 and its 200 day moving average price is $309.32. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.85. The company had revenue of $649.70 million for the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.33 earnings per share. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup lifted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Royal Bank of Canada boosted their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $391.80.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.